News for AVITA Medical, Inc. (RCEL)

VALENCIA, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. ( RCEL, ASX: AVH), a leading therapeutic acute wound company delivering transformativ

AVITA Medical (NASDAQ: RCEL, ASX: AVH) to reveal Q1 2025 financial performance on May 8, 2025, post U.S. market close. Conference call and webcast scheduled

BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. ( IKT) (”œInhibikase” or ”œCompany”), a clinical-stage pharmaceutic

Sixteen abstracts to present real-world findings and clinical innovations across AVITA Medical's expanded portfolio, including RECELL, Cohealyx, and PermeaDerm

AVITA Medical (RCEL) to present 16 abstracts at ABA 2025, showcasing groundbreaking burn and wound care data. Significant findings include over 6,000 re

**media[590882]**

VALENCIA, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. ( RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transfor

**media[585536]**

VALENCIA, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. ( RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transfor

The average of price targets set by Wall Street analysts indicates a potential upside of 73.7% in Avita Medical (RCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

**media[551581]**

On February 20, 2025, Robert Mcnamara, a Director at AVITA Medical Inc (RCEL), purchased 10,000 shares of the company, as reported in the SEC Filing. Following

We came across a bullish thesis on AVITA Medical, Inc. (RCEL) on Substack by Steve Wagner. In this article, we will summarize the bulls’ thesis on RCEL. AVITA Medical, Inc.

The mean of analysts' price targets for Avita Medical (RCEL) points to a 52.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Commercial Revenue: $18.4 million for Q4 2024, a 30% increase compared to Q4 2023.Full-Year Revenue: $64 million for 2024, a 29% increase from $49.8 million in

Feb 14, 2025 / 09:30PM GMTOperator Good day, and thank you for standing by. Welcome to the AVITA Medical fourth-quarter 2024 earnings conference call. (Operator

VALENCIA, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. ( RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transform

AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ETCompany ParticipantsJessica Ekeberg - Director of Investor...

**media[540324]**